Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bixia Tang

Showing results (71-80 of 114) with videos related to

Pageof 12
Sort By:
Innovation (Cambridge (Mass.))|June 17, 2024
IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinomaChuanliang Cui, Juan Li, Yue Yang, et al.
BMC Cancer|May 20, 2022
Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I studyLi Zhou, Xiaowen Wu, Zhihong Chi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2023
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trialXuan Wang, Xiaowen Wu, Yue Yang, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 25, 2023
Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanomaYu Du, Jie Dai, Lili Mao, et al.
Frontiers in Surgery|January 20, 2022
Surgical Outcomes of Vaginal or Cervical MelanomaHui Tian, Xuan Wang, Bin Lian, et al.
Med (New York, N.Y.)|March 20, 2025
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 studyXieqiao Yan, Juan Li, Huayan Xu, et al.
The Oncologist|March 27, 2023
HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese PopulationLi Zhou, Zhiting Shao, Yiqiang Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2021
Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanomaBixia Tang, Jiazhi Mo, Xieqiao Yan, et al.
Journal for Immunotherapy of Cancer|February 26, 2021
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohortXue Bai, Michelle Kim, Gyulnara Kasumova, et al.
Urologic Oncology|February 21, 2024
Natural history of bone-only metastasis in renal cell carcinomaBixia Tang, Rong Duan, Zenan Fan, et al.
Pageof 12

Showing results (71-80 of 114) with videos related to

Sort By:
Pageof 12
Innovation (Cambridge (Mass.))|June 17, 2024
IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinomaChuanliang Cui, Juan Li, Yue Yang, et al.
BMC Cancer|May 20, 2022
Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I studyLi Zhou, Xiaowen Wu, Zhihong Chi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2023
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trialXuan Wang, Xiaowen Wu, Yue Yang, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 25, 2023
Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanomaYu Du, Jie Dai, Lili Mao, et al.
Frontiers in Surgery|January 20, 2022
Surgical Outcomes of Vaginal or Cervical MelanomaHui Tian, Xuan Wang, Bin Lian, et al.
Med (New York, N.Y.)|March 20, 2025
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 studyXieqiao Yan, Juan Li, Huayan Xu, et al.
The Oncologist|March 27, 2023
HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese PopulationLi Zhou, Zhiting Shao, Yiqiang Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2021
Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanomaBixia Tang, Jiazhi Mo, Xieqiao Yan, et al.
Journal for Immunotherapy of Cancer|February 26, 2021
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohortXue Bai, Michelle Kim, Gyulnara Kasumova, et al.
Urologic Oncology|February 21, 2024
Natural history of bone-only metastasis in renal cell carcinomaBixia Tang, Rong Duan, Zenan Fan, et al.
Pageof 12